S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
JANX · Janux Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Janux Therapeutics Inc (JANX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$16.93
-0.27
(-1.60%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$16.93
$16.79
$17.46
52-WEEK RANGE
$16.93
$12.12
$35.34
What's happening
- JANX is down 1.60% today, trading at $16.93. — Live quote
- Volume today (52,825) is well below its 3-month average of 987,910. (Finnhub fundamentals)
- Reports earnings on 2026-11-10 (after market close), 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.35 actual vs. $-0.39 estimated (+10.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 9
Buy 12
Hold 3
Sell 1
Strong sell 0
Aggregate ratings for 2026-10-01 (25 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
JANX
+24.64%
vs S&P 500
+11.86%
1-YEAR RETURN
JANX
-36.08%
vs S&P 500
-50.64%
6-MONTH RETURN
JANX
+13.23%
3-MONTH RETURN
JANX
+5.78%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.35
Est. $-0.39
BEAT +10.7%
2026-04-26 (Q1 2026)
$-0.39
Est. $-0.54
BEAT +27.4%
2026-01-26 (Q4 2025)
$-0.51
Est. $-0.66
BEAT +22.4%
2025-10-26 (Q3 2025)
$-0.39
Est. $-0.63
BEAT +38.1%
Valuation Measures & Ratios
Enterprise Value4$1.01B
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)43.13
Price / Book71.01
EV4 / Revenue41.97
EV4 / EBITDA—
Profit Margin-294.36%
Operating Margin-421.47%
Return on Equity (ROE8)-10.79%
Return on Assets (ROA9)-10.10%
Avg Volume (3M)987,910
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $964.6M | $867.6M | $1.53B | $1.42B | $1.67B |
| P/E | -9.23 | -8.18 | -13.90 | -15.58 | -23.07 |
| Price/Book | 1.04 | 0.92 | 1.56 | 1.44 | 1.65 |
| ROE | -11.26% | -11.26% | -11.24% | -9.23% | -7.14% |
| ROA | -10.37% | -10.31% | -10.71% | -8.85% | -6.88% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short5,684,346
Change from Prior Settlement-3.52%
% of Float—
Days to Cover (Short Ratio)5.86
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 10-Q, filed 2026-08-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -294.4%. Finnhub fundamentals ↗
- Trailing 52-week price return is -36.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on JANX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$31.7M | -$34.2M | -$35.3M | -$45.1M | -$34.9M | -$35.8M | -$13.8M | -$20.2M |
| Net income | -$22.0M | -$24.4M | -$24.3M | -$33.9M | -$23.5M | -$28.1M | -$6.0M | -$14.8M |
| EPS (diluted) | $-0.35 | $-0.39 | $-0.39 | $-0.55 | $-0.38 | $-0.51 | $-0.11 | $-0.30 |
| EPS (basic) | $-0.35 | $-0.39 | $-0.39 | $-0.55 | $-0.38 | $-0.51 | $-0.11 | $-0.30 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $1.01B | $1.03B | $1.00B | $1.02B | $1.03B | $1.05B | $1.06B | $695.0M |
| Total liabilities | $79.7M | $86.7M | $44.7M | $48.2M | $41.7M | $38.3M | $38.7M | $38.9M |
| Stockholders' equity | $928.0M | $941.5M | $956.8M | $976.6M | $990.5M | $1.01B | $1.02B | $656.1M |
| Total current assets | $983.3M | $1.00B | $975.9M | $998.1M | $1.01B | $1.02B | $1.03B | $666.3M |
| Total current liabilities | $60.2M | $58.9M | $25.0M | $27.8M | $21.4M | $17.5M | $17.5M | $17.2M |
| Cash & equivalents | $27.8M | $51.8M | $52.3M | $48.4M | $52.4M | $73.7M | $430.6M | $26.8M |
| Marketable securities (current) | $943.1M | $904.6M | $914.2M | $940.6M | $943.6M | $940.4M | $594.6M | $631.3M |
| Accounts receivable | $149.0K | $35.0M | $0 | — | — | — | — | — |
| Property, plant & equipment | $3.3M | $3.5M | $3.9M | $4.3M | $4.7M | $4.9M | $4.9M | $5.4M |
| Other non-current assets | $2.9M | $3.9M | $2.6M | $2.6M | $2.7M | $2.8M | $2.9M | $2.8M |
| Accounts payable | $3.0M | $3.4M | $5.0M | $3.4M | $3.5M | $2.4M | $4.0M | $2.5M |
| Accrued liabilities | $19.5M | $15.5M | $17.6M | $22.2M | $16.0M | $13.3M | $11.7M | $13.0M |
| Deferred revenue (current) | $35.1M | $37.6M | $0 | — | — | — | $0 | $0 |
| Common stock & paid-in capital | $61.0K | $60.0K | $60.0K | $60.0K | $59.0K | $59.0K | $59.0K | $52.0K |
| Retained earnings | -$397.7M | -$375.7M | -$351.4M | -$319.4M | -$295.1M | -$261.3M | -$237.8M | -$217.5M |
| Accumulated other comprehensive income (loss) | -$2.3M | $576.0K | $4.3M | $4.6M | $3.7M | $3.8M | $2.2M | $7.8M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $12.5M | -$12.3M | -$28.5M | -$12.9M | -$23.8M | -$17.0M | -$16.7M | -$2.2M |
| Investing cash flow | -$38.8M | $8.3M | $29.5M | $8.3M | $1.6M | -$340.4M | $33.9M | $12.7M |
| Financing cash flow | $2.2M | $3.5M | $2.9M | $493.0K | $954.0K | $554.0K | $386.6M | $1.6M |
| Free cash flow | $12.3M | -$12.6M | -$28.6M | -$12.9M | -$24.3M | -$17.4M | -$16.8M | -$2.3M |
| Capital expenditures | $202.0K | $273.0K | $106.0K | $93.0K | $473.0K | $371.0K | $42.0K | $25.0K |
| Share-based compensation | $9.1M | $9.3M | $29.5M | $9.0M | $11.0M | $10.7M | $27.4M | $15.4M |
| Deferred income taxes | — | — | — | — | — | — | $0 | — |
| Change in accounts receivable | -$34.9M | $35.0M | — | — | $0 | $0 | — | — |
| Change in accounts payable | -$342.0K | -$1.6M | $1.7M | -$168.0K | $1.1M | -$1.6M | $1.6M | $1.2M |
| Purchases of investments | $144.8M | $112.8M | $123.3M | $118.0M | $92.7M | $371.3M | $24.0M | $32.5M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$157.7M | -$98.8M | -$73.0M | -$67.1M | -$32.9M |
| Net income | -$113.6M | -$69.0M | -$58.3M | -$63.1M | -$32.7M |
| EPS (diluted) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 |
| EPS (basic) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-1.39 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $1.00B | $1.06B | $380.4M | $364.0M | $379.8M |
| Total liabilities | $44.7M | $38.7M | $36.1M | $43.3M | $13.5M |
| Stockholders' equity | $956.8M | $1.02B | $344.3M | $320.7M | $366.3M |
| Total current assets | $975.9M | $1.03B | $349.2M | $332.4M | $377.0M |
| Total current liabilities | $25.0M | $17.5M | $13.0M | $16.5M | $12.8M |
| Cash & equivalents | $52.3M | $430.6M | $19.2M | $51.4M | $35.6M |
| Marketable securities (current) | $914.2M | $594.6M | $324.8M | $275.6M | $339.4M |
| Property, plant & equipment | $3.9M | $4.9M | $7.0M | $7.1M | $1.4M |
| Other non-current assets | $2.6M | $2.9M | $2.5M | $1.4M | $392.0K |
| Accounts payable | $5.0M | $4.0M | $2.4M | $2.2M | $2.5M |
| Accrued liabilities | $17.6M | $11.7M | $7.4M | $8.2M | $3.8M |
| Deferred revenue (current) | — | $0 | $1.7M | $5.4M | $5.2M |
| Common stock & paid-in capital | $60.0K | $59.0K | $46.0K | $42.0K | $41.0K |
| Retained earnings | -$351.4M | -$237.8M | -$168.8M | -$110.5M | -$47.4M |
| Accumulated other comprehensive income (loss) | $4.3M | $2.2M | $665.0K | -$1.5M | -$270.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$82.2M | -$43.8M | -$50.6M | -$42.9M | -$17.0M |
| Investing cash flow | -$301.0M | -$258.0M | -$41.2M | $58.3M | -$341.0M |
| Financing cash flow | $4.9M | $713.2M | $59.5M | $500.0K | $386.5M |
| Free cash flow | -$83.3M | -$44.2M | -$52.4M | -$49.4M | -$18.5M |
| Capital expenditures | $1.0M | $359.0K | $1.9M | $6.4M | $1.5M |
| Share-based compensation | $40.2M | $33.0M | $20.0M | $17.2M | $6.9M |
| Deferred income taxes | — | $0 | $0 | $0 | $0 |
| Change in accounts receivable | — | — | — | $0 | -$8.0M |
| Change in accounts payable | $977.0K | $1.6M | $277.0K | -$294.0K | $2.1M |
| Purchases of investments | $705.2M | $470.6M | $317.3M | $294.4M | $473.6M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding JANX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-11 to 2026-07-31
Recent transactions
- Insiders have net sold 6,097 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: Campbell David Alan (President and CEO) — Gift of 123,840 shares on 2026-07-31.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)6,097 sh(2 txns)
Net Shares-6,097
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Campbell David Alan | President and CEO | Gift | 2026-07-31 | 123,840 |
| RA CAPITAL MANAGEMENT, L.P. | Reporting person | Grant / award | 2026-06-11 | 5,500 |
| Simson Jake | Reporting person | Grant / award | 2026-06-11 | 5,500 |
| Kung Winston | Reporting person | Grant / award | 2026-06-11 | 5,500 |
| Hernday Natasha | Reporting person | Grant / award | 2026-06-11 | 5,500 |
| DOBMEIER ERIC | Reporting person | Grant / award | 2026-06-11 | 5,500 |
| CAPPS VICKIE L | Reporting person | Grant / award | 2026-06-11 | 5,500 |
| Barrett Ronald W | Reporting person | Grant / award | 2026-06-11 | 5,500 |
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Open market sale | 2026-06-02 | 4,059 |
| Dobek Maria | Vice President, Accounting | Open market sale | 2026-05-11 | 2,038 |
| Go William | Chief Medical Officer | Grant / award | 2026-02-02 | 44,000 |
| Meyer Andrew Hollman | Chief Business Officer | Open market sale | 2026-01-02 | 1,879 |
| DiRaimondo Thomas | Chief Scientific Officer | Open market sale | 2026-01-02 | 2,505 |
| Winter Charles M. | Chief Technical Officer | Open market sale | 2026-01-02 | 2,401 |
| McIver Zachariah | Chief Medical Officer | Open market sale | 2026-01-02 | 2,714 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-31 | Campbell David Alan | President and CEO | Gift | 123,840 | $0.00 |
| 2026-07-08 | Campbell David Alan | President and CEO | Option exercise | 7,000 | $4.21 |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Grant / award | 5,500 | $0.00 |
| 2026-06-11 | Simson Jake | Reporting person | Grant / award | 5,500 | $0.00 |
| 2026-06-11 | Kung Winston | Reporting person | Grant / award | 5,500 | $0.00 |
| 2026-06-11 | Hernday Natasha | Reporting person | Grant / award | 5,500 | $0.00 |
| 2026-06-11 | DOBMEIER ERIC | Reporting person | Grant / award | 5,500 | $0.00 |
| 2026-06-11 | CAPPS VICKIE L | Reporting person | Grant / award | 5,500 | $0.00 |
| 2026-06-11 | Barrett Ronald W | Reporting person | Grant / award | 5,500 | $0.00 |
| 2026-06-02 | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Open market sale | 4,059 | $14.03 |
| 2026-05-11 | Dobek Maria | Vice President, Accounting | Open market sale | 2,038 | $14.17 |
| 2026-02-02 | Go William | Chief Medical Officer | Grant / award | 44,000 | $0.00 |
| 2026-01-02 | Meyer Andrew Hollman | Chief Business Officer | Open market sale | 1,879 | $13.73 |
| 2026-01-02 | DiRaimondo Thomas | Chief Scientific Officer | Open market sale | 2,505 | $13.73 |
| 2026-01-02 | DiRaimondo Thomas | Chief Scientific Officer | Grant / award | 31,400 | $0.00 |
| 2026-01-02 | Campbell David Alan | President and CEO | Open market sale | 8,072 | $13.73 |
| 2026-01-02 | Campbell David Alan | President and CEO | Grant / award | 96,600 | $0.00 |
| 2026-01-02 | Winter Charles M. | Chief Technical Officer | Open market sale | 2,401 | $13.73 |
| 2026-01-02 | Winter Charles M. | Chief Technical Officer | Grant / award | 28,600 | $0.00 |
| 2026-01-02 | McIver Zachariah | Chief Medical Officer | Open market sale | 2,714 | $13.73 |
| 2026-01-02 | McIver Zachariah | Chief Medical Officer | Grant / award | 29,000 | $0.00 |
| 2026-01-02 | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Grant / award | 36,000 | $0.00 |
| 2026-01-02 | Dobek Maria | Vice President, Accounting | Open market sale | 1,462 | $13.73 |
| 2026-01-02 | Dobek Maria | Vice President, Accounting | Grant / award | 18,935 | $0.00 |
| 2025-12-01 | Meyer Andrew Hollman | Chief Business Officer | Option exercise | 3,333 | $10.59 |
| 2025-12-01 | Meyer Andrew Hollman | Chief Business Officer | Open market sale | 2,700 | $32.85 |
| 2025-12-01 | Meyer Andrew Hollman | Chief Business Officer | Open market sale | 633 | $33.52 |
| 2025-11-14 | Meyer Andrew Hollman | Chief Business Officer | Option exercise | 3,333 | $10.59 |
| 2025-11-14 | Meyer Andrew Hollman | Chief Business Officer | Open market sale | 3,333 | $30.00 |
| 2025-10-28 | Meyer Andrew Hollman | Chief Business Officer | Option exercise | 9,999 | $4.21 |
| 2025-10-28 | Meyer Andrew Hollman | Chief Business Officer | Option exercise | 6,666 | $10.59 |
| 2025-10-28 | Meyer Andrew Hollman | Chief Business Officer | Open market sale | 16,665 | $30.06 |
| 2025-06-11 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Grant / award | 3,750 | $0.00 |
| 2025-06-11 | Barrett Ronald W | Reporting person | Grant / award | 3,750 | $0.00 |
| 2025-06-11 | CAPPS VICKIE L | Reporting person | Grant / award | 3,750 | $0.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 03:44 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-31 | 4 | 2026-07-31 | View on SEC.gov → |
| 2026-07-10 | 4 | 2026-07-08 | View on SEC.gov → |
| 2026-06-23 | 8-K | 2026-06-23 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
| 2026-06-12 | 4 | 2026-06-11 | View on SEC.gov → |
Recent news
Headlines about JANX (Janux Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
JANX Oct 2026 30.000 call (JANX261016C00030000) interactive stock chart
Yahoo Finance UK · 2026-10-17 -
JANX Jan 2027 15.000 put (JANX270115P00015000) Interactive Stock Chart - Yahoo Finance
Yahoo! Finance Canada · 2026-10-16 -
Janux Therapeutics, Inc. (JANX) stock price, news, quote and history
Yahoo Finance Australia · 2026-10-15 -
Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now?
Yahoo Finance · 2026-10-13 -
Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run
Yahoo Finance · 2026-10-10 -
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Yahoo Finance · 2026-09-30 -
Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?
Yahoo Finance · 2026-09-29 -
Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey
Yahoo Finance · 2026-09-27
No headlines in this category right now — try “All”.